Schedule a Meeting

LumineticsCore (formerly known as IDx-DR), a device that was previously covered on DocWire News, is capable of diagnosing diabetic retinopathy without human intervention. The system is the first FDA-approved autonomous artificial intelligence (AI), using its software to analyze images from a retinal camera for evidence of lesions. These lesions are a sign of retinal damage that is associated with diabetes and are what physicians look for in diagnosing eye disease in diabetic patients. Recently, we took the time to check in with IDx CEO and Founder Michael Abramoff, MD, PhD, about how this innovative technology has fared in the past year.

LumineticsCore (formerly known as IDx-DR) was only in place at the University of Iowa Health Care when we spoke with Dr. Abramoff last summer, however, he notes that the technology is now implemented in over 20 locations in the country. Some of the institutions utilizing this AI technology include:

  • Blessing Health
  • Johns Creek Primary Care
  • Johns Hopkins
  • LCMC
  • University of Iowa Health Care